by The global Plasma Protease C1-inhibitor Treatment Market is estimated to be valued at US$ 5432.28 million in 2023 and is expected to exhibit a CAGR of 18% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Plasma protease C1-inhibitor treatment targets hereditary angioedema by providing the missing or malfunctioning C1-inhibitor that regulates various functions of the immune system. These treatment options offer patients alternative treatment methods to manage acute hereditary angioedema attacks and prevent future attacks.
Market key trends:
The increasing prevalence of hereditary angioedema is a key driver augmenting the demand for plasma protease C1-inhibitor treatment globally. Hereditary angioedema is a rare genetic disease characterized by recurrent episodes of severe swelling or edema in various body parts including face, abdominal area, limbs, and airway swelling. According to rare diseases database, the estimated prevalence of Hereditary Angioedema ranges between 1 in 10,000 and 1 in 50,000 individuals globally. Moreover, various government initiatives to improve treatment facilities for rare diseases and rising awareness about hereditary angioedema treatment options are also contributing to the growth of this market. These trends are expected to continue over the forecast period.
SWOT Analysis
Strength: Plasma Protease C1-inhibitor Treatment has shown clinical efficacy for reducing attacks in HAE patients, providing a reliable treatment option.
Weakness: High costs associated with plasma Protease C1-inhibitor Treatment limits widespread adoption. Intravenous administration also poses convenience challenges for patients.
Opportunity: Unmet needs remain for on-demand therapy and broader prevention of attacks. Self-administration formulations could improve treatment experience.
Threats: Pipeline of oral therapies and prophylactic alternatives from competitors may capture market share. Regulatory approvals will influence reimbursement and accessibility.
Key Takeaways
The Global Plasma Protease C1-Inhibitor Treatment Market Size is expected to witness high growth over the forecast period of 2023 to 2030. The global Plasma Protease C1-inhibitor Treatment Market is estimated to be valued at US$ 5432.28 million in 2023 and is expected to exhibit a CAGR of 18% over the forecast period 2023 to 2030.
North America dominates currently due to established patients base and favorable reimbursement. Asia Pacific shows most potential for growth with rising diagnosis rates and economic expansion improving access.
Key players: Key players operating in the Plasma Protease C1-inhibitor Treatment market are CSL Behring LLC, Takeda Pharmaceutical Company Limited, Ionis Pharmaceuticals, Inc., Pharming Technologies B.V., Centogene AG, BioCryst Pharmaceuticals, and KalVista Pharmaceuticals, Inc. CSL Behring LLC leads with market share from HAEGARDA, but pipeline therapies from Ionis Pharmaceuticals and KalVista Pharmaceuticals could capture significant demand if successfully commercialized.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
